# Trevogrumab

> An anti-myostatin antibody (Regeneron) now studied in obesity combinations to cut lean-mass loss and deepen fat loss alongside semaglutide.

- Also known as: REGN1033
- Class: Growth Hormone, Metabolic
- FDA approved: No
- Canonical page: https://www.americanpeptide.com/catalog/trevogrumab

## Overview

Trevogrumab is a monoclonal antibody from Regeneron that neutralizes mature myostatin. After an earlier life in sarcopenia research, it has re-emerged squarely in the GLP-1 era: as a muscle-sparing add-on to incretin weight-loss drugs, and as one leg of a triple combination designed to maximize fat loss while protecting muscle.

Trevogrumab is the clearest worked example of the muscle-preservation thesis. In trial data, semaglutide alone reduced both fat (~−15.7%) and lean mass (~−6.5%); adding trevogrumab roughly halved the lean-mass loss (to ~−3.3 to −3.8%) while increasing fat loss (up to ~−19.1%). The triple combination of semaglutide + trevogrumab + garetosmab (an anti-activin-A antibody) produced the most favorable body-composition profile of all — heavy fat loss with minimal lean loss — and is being tested in the COURAGE program expected to read out in late 2026.

It is a monoclonal antibody (~150 kDa) and an investigational agent. Its inclusion rounds out the myostatin axis with a mature-myostatin neutralizer, complementing apitegromab’s precursor-selective approach.

## Mechanism

Binds and neutralizes mature myostatin (GDF-8), removing its brake on muscle growth via the ActRIIB/Smad pathway. Used to offset the lean-mass loss that accompanies large GLP-1-driven weight loss.

## Chemistry

| Property | Value |
| --- | --- |
| Molecular weight | 150000 Da |

## Research areas

Studied in: Obesity, Muscle preservation, GLP-1 muscle preservation, Body composition.

Guides on this site:

- [Weight Loss & Metabolic Health](https://www.americanpeptide.com/research-areas/weight-loss): Incretin and metabolic peptides studied for glycemic control and fat loss.
- [Growth Hormone & Body Composition](https://www.americanpeptide.com/research-areas/growth-hormone-axis): Secretagogues studied for GH release, IGF-1, and body composition.

## Key research

- GLP-1 muscle preservation — roughly halved semaglutide-associated lean-mass loss while deepening fat loss in trial data.
- Triple combination — semaglutide + trevogrumab + garetosmab gave the best body-composition profile; COURAGE trial expected to complete late 2026.
- Mature-myostatin neutralizer — binds active myostatin, complementing precursor-selective antibodies.
- Sarcopenia origins — earlier studied for age-related muscle loss before the obesity pivot.
- Investigational — not FDA-approved.

## Storage, handling & synthesis

**Storage.** Stored refrigerated (2–8 °C), protected from light and freezing, not shaken; investigational handling per trial protocol.

**Handling.** A large glycosylated antibody sensitive to freezing, heat, and agitation, which can cause aggregation.

**Synthesis.** Trevogrumab is a recombinant monoclonal antibody (~150 kDa) made in mammalian cell culture, characterized with antibody-grade analytics (glycan/charge-variant profiling, mass spectrometry, binding/potency bioassay) — not a synthetic peptide.

## FAQs

### What is trevogrumab?

A Regeneron monoclonal antibody that neutralizes myostatin, studied as a muscle-sparing add-on to GLP-1 weight-loss drugs and in a triple combination with semaglutide and garetosmab.

### What does adding it to semaglutide do?

In trial data it roughly halved the lean-mass loss seen with semaglutide alone while increasing fat loss — the core "quality of weight loss" idea.

### Is this medical advice?

No — this is a research and educational reference. Trevogrumab is an investigational antibody, not an approved drug.

## Latest research

Recent trials and publications mentioning Trevogrumab, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily).

### Recent trials

- [A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation](https://clinicaltrials.gov/study/NCT06299098) — ACTIVE_NOT_RECRUITING · PHASE2 · NCT06299098

---

Source: AmericanPeptide.com — https://www.americanpeptide.com/catalog/trevogrumab
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.